Condition: Recurrent or Metastatic Nasopharyngeal Carcinoma · Sponsor: Ming-Yuan Chen
This is a prospective, single-arm Phase 2 study to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with PD-1 blockade in patients with recurrent (not unable to locally curative treatment) or metastatic NPC who failed at least first-line platinum-containing standard regimen and/or anti PD-1/L1.
This description comes directly from the study's public registry record.
Mingyuan Chen, Doctor · 18124188280 · chmingy@mail.sysu.edu.cn
Jijin Yao, Doctor · 15692424219 · yaojj23@mail.sysu.edu.cn
Always discuss trial participation with your own doctor first.
| The Fifth Affiliated Hospital, Sun Yat-sen University | Zhuhai, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06472713